BC Week In Review | Jun 22, 2017
Clinical News

FDA approves Hologic's Aptima HSV 1 & 2 assay

FDA approved the Aptima HSV 1 & 2 assay from Hologic Inc. (NASDAQ:HOLX) to diagnose and differentiate HSV-1 and HSV-2 infection. The in vitro nucleic acid amplification test is designed to run on the company’s...
Items per page:
1 - 1 of 1